Pfizer expects $29B in COVID-19 vaccine sales next year
Global News
Pfizer's COVID-19 vaccine has become one of the most widely used inoculation in the United States and Europe.
Pfizer Inc on Tuesday forecast better-than-expected $29 billion in sales from its COVID-19 vaccine for 2022 and said it was seeking to sign more deals with countries for the shot that it has developed with German partner BioNTech.
The company said while it had the capacity to produce 4 billion doses in 2022, it was currently expecting to recognize sales from 1.7 billion doses in 2022, suggesting that the forecast could move higher as Pfizer signs more vaccine deals.
Pfizer, which equally splits expenses and profit for the shot with German partner BioNTech, also raised its sales forecast for the vaccine to $36 billion for 2021, suggesting that the shot will account for as much as 44 per cent of its total sales for the year.
Wall Street on average expected sales of $22.15 billion from the vaccine for 2022, according to eight analysts polled by Refinitiv.
Pfizer’s COVID-19 vaccine, which was the first shot to receive U.S. authorization when it was cleared for emergency use in December, has become one of the most widely used inoculation in the United States and Europe.
Its sales have vastly outpaced those sold by rivals Moderna Inc and Johnson & Johnson, which are struggling with production snags and safety concerns.
Pfizer’s vaccine is recommended or the only one permitted for use in younger populations in many countries, the company’s chief scientific officer, Mikael Dolsten, said.
The employee was indicted for allegedly distributing personal information of TD Bank customers, the latest criminal probe to hit the U.S. arm of the Canadian financial institution.
Stock markets were rising broadly higher on news of Donald Trump's U.S. election victory on Wednesday. Here's how investors say you should adjust your portfolio.
The Bank of Canada's Carolyn Rogers says improving housing affordability ultimately requires reaching a balance between supply and demand, which she says will take time.
Donald Trump was previously a crypto skeptic but changed his mind and took a favorable view of cryptocurrencies ahead of the election.
Canadians continue to make payments on their mortgages, but there are signs of stress bubbling up on other credit products, which CMHC warns could continue to spread to home loans.
Canadians continue to make payments on their mortgages, but there are signs of stress bubbling up on other credit products, which CMHC warns could continue to spread to home loans.
Bell Canada will use $4.2 billion of the proceeds it got from selling its stake in Maple Leaf Sports & Entertainment to Rogers Communications to fund this acquisition.
With the costs of pet ownership rising, the Competition Bureau sees an opportunity to drive down the prices of medication by expanding distribution to pharmacies.
Major North American carriers with international operations are cashing in on a booming demand for overseas travel and a resurgence in business bookings.